LUCD Lucid Diagnostics Inc.

0.6235USD+3.92%Mkt Cap: 119.06M $P/E: —

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophage…

Key Statistics

Company
Market Cap119.06M USD
Enterprise Value105.01M USD
Revenue (TTM)5.45M USD
Gross Profit-1.96M USD
Net Income (TTM)-58.01M USD
Revenue/Share0.04 USD
Last Price0.6235 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.64
PEG—
EV/EBITDA-2.11
EV/Revenue19.28
P/S21.04
P/B10.53
EPS (TTM)-0.44
EPS (Forward)-0.17
52W Range
0.500011% of range1.629
52W High1.629 USD
52W Low0.5000 USD
Profitability
Gross Margin-41.73%
Oper. Margin-868.45%
EBITDA Margin0.00%
Profit Margin-1232.68%
ROE-530.45%
ROA-143.43%
Growth
Revenue Growth26.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.48M USD
CapEx (TTM)197.00K USD
FCF Margin-485.38%
FCF Yield-22.20%
Net Debt-9.56M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity2.36
Current Ratio1.33
Quick Ratio1.29
Book Value/Sh0.06 USD
Cash/Share0.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.000 USD
Upside (mean)+541.5%
Target Range2.000 USD – 9.500 USD
2.000+541.5% to mean9.500
# Analysts5
Ownership
Shares Out.190.95M
Float140.76M
Insiders26.50%
Institutions32.74%
Short Interest
Short Ratio13.8d
Short % Float8.64%
Short % Out.6.72%
Shares Short12.83M
Short (prev mo.)12.83M
Technical
SMA 500.8927 (-30.2%)
SMA 2001.086 (-42.6%)
Beta1.12
S&P 52W Chg16.45%
Avg Vol (30d)1.35M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)28.4
MACD-0.0797
MACD Signal-0.0605
MACD Hist.-0.0192
BB Upper0.9609 USD
BB Middle0.7676 USD
BB Lower0.5743 USD
BB Width50.36%
ATR (14)0.0648 USD
Vol Ratio (20d)1.05x